Michael Frank, CEO and Chairman of Revive Therapeutics discusses the Phase 3 trial of Bucillamine, a well known prescribed anti-inflammatory drug in Japan and South Korea, as an oral at-home pill treatment option for mild-moderate to severe COVID-19.
Michael Frank, CEO and Chairman of Revive
Stepped in as CEO in 2019 and took Revive’s market cap from just $1.4 million to over $100M
Strong background in operations, business development, M&A, the capital markets and has been instrumental in advising several early stage software companies including a number in the cannabis sector over the last few years
Currently the President of Mifran Consulting, providing advisory services to emerging technology companies in a number of key verticals.